PRECISION BIOSCIENCES INC
NASDAQ: DTIL (Precision BioSciences, Inc.)
Last update: 21 hours ago7.17
-0.07 (-0.97%)
| Previous Close | 7.24 |
| Volume | 191,403 |
| Price / Earnings (Forward) | 11.78 |
| Price / Sales | 3.24 |
| Price / Book | 4.37 |
| 52 Weeks Range |
| Profit Margin | -42.99% |
| Operating Margin (TTM) | -76,248.27% |
| Diluted EPS (TTM) | -2.87 |
| Quarterly Revenue Growth (YOY) | -99.80% |
| Total Debt/Equity (MRQ) | 60.30% |
| Current Ratio (MRQ) | 6.62 |
| Operating Cash Flow (TTM) | -58.52 M |
| Levered Free Cash Flow (TTM) | 6.86 M |
| Return on Assets (TTM) | -17.83% |
| Return on Equity (TTM) | -50.81% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Precision BioSciences, Inc. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -0.83 |
|
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 10.94% |
| % Held by Institutions | 42.73% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Octagon Capital Advisors Lp | 30 Jun 2026 | 1,350,000 |
| Empery Asset Management, Lp | 30 Jun 2026 | 776,093 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |